NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. ('HEALWELL' or the 'Company') (TSX: AIDX), a data science and AI company focused on preventative care, is pleased to announce that it has entered into an agreement pursuant to which Clarus Securities Inc.

2024年5月6日，不向美国新闻通讯社（NEWS WIRE SERVICES）分发或在美国多伦多传播（Global NEWSWIRE）——HEALWELL AI Inc.（“HEALWELL”或“公司”）（TSX:AIDX），一家专注于预防保健的数据科学和人工智能公司，很高兴地宣布，它已经签署了一项协议，根据该协议，Clarus Securities Inc。

and Eight Capital, as lead underwriters and co-bookrunners, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase 11,851,900 units of the Company (the “Units”), on a “bought deal” private placement basis, at a price of $1.35 per Unit (the “Issue Price”) for gross proceeds of $16,000,065 (the “Offering”).

作为主承销商和联席账簿管理人，八大资本将与一个承销商财团（统称“承销商”）一起，以“买入交易”私募方式，以每单位1.35美元的价格（“发行价格”）购买公司11851900个单位（“单位”），总收益为16000065美元（“发行”）。

Each Unit will be comprised of one Class A subordinate voting share of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant, a “Warrant”) of the Company. Each Warrant shall entitle the holder thereof to purchase one Share at an exercise price of $1.80 for a period of two (2) years following the closing of the Offering.

每个单位将由本公司的一股A类次级有表决权股份（以下简称“股份”）和本公司的一份认股权证（每份认股权证，以下简称“认股权证”）的一半组成。每份认股权证的持有人有权在发售结束后的两（2）年内以1.80美元的行权价格购买一股股票。

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is two (2) business days prior to the closing of the Offering. If the over-allotment option is exercised in full, an additional $2,400,010 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $18,400,075.

本公司已同意授予承销商超额配售权，以发行价格额外购买15%的股份，可在发售结束前两（2）个营业日或之前的任何时间全部或部分行使。如果超额配售权被全额行使，将根据发售额外筹集2400010美元，发售总收益将为18400075美元。

The Company intends to use the net proceeds of the Offering for growth initiatives and for general corporate and working capital purposes. The closing of the Offering is expected to occur on or about May 24, 2024, or such other date as the Company and the Underwriters may agree and is.

公司打算将此次发行的净收益用于增长计划以及一般公司和营运资本目的。本次发行的结束日期预计为2024年5月24日左右，或公司和承销商可能同意的其他日期。